Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study
May 11, 2023 09:05 ET
|
Palisade Bio, Inc.
Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing efficacy Company expects enrollment to be...
Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148
April 06, 2023 09:00 ET
|
Palisade Bio, Inc.
Carlsbad, CA, April 06, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148
April 05, 2023 08:35 ET
|
Palisade Bio, Inc.
Enrollment triggers milestone payment Carlsbad, CA and Shanghai, China, April 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a...
Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
April 03, 2023 08:30 ET
|
Palisade Bio, Inc.
Carlsbad, CA, April 03, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is...
Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update
March 23, 2023 08:05 ET
|
Palisade Bio, Inc.
Phase 2 topline data readout for prevention of post-surgical abdominal adhesions on track for Q2 2023 Strong balance sheet with sufficient cash expected to fund operations into mid-2024 ...
Palisade Bio Receives Intention to Grant from European Patent Office for LB1148 Patent
March 01, 2023 09:05 ET
|
Palisade Bio, Inc.
Carlsbad, CA, March 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a clinical stage biopharmaceutical company advancing therapies for acute and chronic...
Palisade Bio Promotes Robert McRae to Chief Operating Officer
February 08, 2023 08:35 ET
|
Palisade Bio, Inc.
Mr. McRae is an industry veteran with a proven track record of operational, clinical, and strategic business development execution Carlsbad, CA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Palisade...
Palisade Bio Further Strengthens Balance Sheet with Early Exercise of Warrants Resulting in Cash Proceeds of $4.9 Million
January 10, 2023 08:35 ET
|
Palisade Bio, Inc.
Proceeds expected to extend cash runway to fund operations into the second half of 2024 Carlsbad, CA, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage...
Palisade Bio to Present at the Virtual Investor 2023 Companies to Watch Event
January 09, 2023 08:45 ET
|
Palisade Bio, Inc.
Live video webcast on Tuesday, January 17th at 3:00 PM ET Carlsbad, CA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company...
Palisade Bio Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
January 04, 2023 17:15 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...